Search results for "From ACP Journal Club"
In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo
Based on this and previous trials, low-dose colchicine should be considered as anti-inflammatory therapy for secondary prevention after myocardial infarction (MI) in patients at high risk for cardiovascular (CV) events, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2024/05/10/7.htm
10 May 2024
In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use
The number of patients who received combination therapy with an SGLT-2 inhibitor and a GLP-1 receptor agonist in a recent review was too small to guide practice, but it's likely that more patients will soon be on this regimen, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/11/08/7.htm
8 Nov 2024
In HF, T2D, CKD, or atherosclerotic CVD, SGLT-2 inhibitors reduce HF hospitalizations and CV mortality
Recent research on newer classes of diabetes drugs indicates that dysglycemia may not be a prerequisite to benefit from their cardiovascular and renal benefits, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/11/08/6.htm
8 Nov 2024
In adults with BMI ≥27 kg/m2 and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk
The new drugs known as “twincretins” represent a major breakthrough for patients with overweight or obesity, prediabetes, or diabetes, but obstacles will include supply, lack of cost-effectiveness evidence, and insurance coverage, an ACP Journal club commentary said.
https://diabetes.acponline.org/archives/2023/11/10/7.htm
10 Nov 2023
KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD
Sodium-glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs) are now recommended for more patients with chronic kidney disease (CKD), but data are needed on their cost-effectiveness, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/05/12/7.htm
12 May 2023
In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA1c vs. daily basal insulin analogues at 52 wk
An ACP Journal Club commentary cautioned that although a recent industry-funded trial was designed to approximate real-world practice, certain factors may still limit the generalizability of its findings.
https://diabetes.acponline.org/archives/2024/01/12/7.htm
12 Jan 2024
In latent autoimmune diabetes in adults, mortality was similar to T2DM but retinopathy was higher at 5.9 y
If confirmed, the findings of different disease trajectories among patients with latent autoimmune diabetes in adults could eventually merit reclassification of the types of diabetes, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/01/12/6.htm
12 Jan 2024
In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary
A recent systematic review of the beneficial and harmful effects of 15 glucagon-like peptide-1 receptor agonists (GLP-1 RAs) should be helpful to clinicians and suggests which drugs are likely to dominate the market in the next few years, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/05/10/8.htm
10 May 2024
In T2DM, periconceptional, noninsulin, second-line antidiabetes medications were not linked to major congenital malformations vs. insulin
A new study provides some reassurance to patients who unintentionally become pregnant while taking diabetes drugs but should be interpreted with caution because the number of infants exposed was low and only pregnancies resulting in live births were included, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/04/12/7.htm
12 Apr 2024
In adults with metabolic dysfunction, the MAF-5 score predicted risk for liver fibrosis (AUC range, 0.73 to 0.81)
The new Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) score could potentially identify patients in primary care who are at risk for progressive fibrosis and facilitate interventions and treatment, but it needs to be prospectively validated, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/10/11/6.htm
11 Oct 2024